Metraipolis › archive › dc_17a2cd6fddbb

Sex differences in gene expression with galactosylceramide treatment in Cln3Δex7/8 mice — Europe PMC PMID:33006978

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/33006978
DOI: 10.1371/journal.pone.0239537
License (as archived): CC0-1.0
Archived: 2026-11-07T09:51:17.165Z
SHA-256 of the archived text: 0ae099c6c9874a875326f115b3ee777b8b46036d19480d8bbf631f6235087f2f
Stable URL of this page: https://metraipolis.com/documento/dc_17a2cd6fddbb

How to cite

Sex differences in gene expression with galactosylceramide treatment in Cln3Δex7/8 mice — Europe PMC PMID:33006978 — Europe PMC (en), https://europepmc.org/article/MED/33006978 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_17a2cd6fddbb (Metraipolis archive dc_17a2cd6fddbb, sha256 0ae099c6c9874a875326f115b3ee777b8b46036d19480d8bbf631f6235087f2f)

BibTeX

@misc{dc17a2cd6fddbb,
  title = {Sex differences in gene expression with galactosylceramide treatment in Cln3Δex7/8 mice — Europe PMC PMID:33006978},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33006978},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_17a2cd6fddbb; sha256 0ae099c6c9874a875326f115b3ee777b8b46036d19480d8bbf631f6235087f2f},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33006978. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: CLN3 disease is caused by mutations in the CLN3 gene. The purpose of this study is to discern global expression patterns reflecting therapeutic targets in CLN3 disease. Methods: Differential gene expression in vehicle-exposed mouse brain was determined after intraperitoneal vehicle/Galactosylceramide (GalCer) injections for 40 weeks with GeneChip Mouse Genome 430 2.0 arrays. Results: Analysis identified 66 genes in male and 30 in female brains differentially expressed in GalCer-treated versus vehicle-exposed Cln3Δex7/8 mice. Gene ontology revealed aberrations of biological function including developmental, cellular, and behavioral processes. GalCer treatment altered pathways of long-term potentiation/depression, estrogen signaling, synaptic vesicle cycle, ErbB signaling, and prion diseases in males, but prolactin signaling, selenium compound metabolism and steroid biosynthesis in females. Gene-gene network analysis highlighted networks functionally pertinent to GalCer treatment encompassing motor dysfunction, neurodegeneration, memory disorder, inflammation and astrogliosis in males, and, cataracts, inflammation, astrogliosis, and anxiety in females. Conclusions: This study sheds light on global expression patterns following GalCer treatment of Cln3Δex7/8 mice. Understanding molecular effects of GalCer on mouse brain gene expression, paves the way for personalized strategies for treating this debilitating disease in humans.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-10-02).
Identificativi: PMID 33006978 · PMCID PMC7531864 · DOI 10.1371/journal.pone.0239537.
Descrittori MeSH principali: Sex Characteristics.
Pagina: https://europepmc.org/article/MED/33006978 — https://doi.org/10.1371/journal.pone.0239537. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T09:45:11.563Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.